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Abstract
In the past decade, the spleen tyrosine kinase (Syk) has shown a high potential for the discovery of new treatments for
inflammatory and autoimmune disorders. Pharmacological inhibitors of Syk catalytic site bearing therapeutic potential have
been developed, with however limited specificity towards Syk. To address this topic, we opted for the design of drug-like
compounds that could impede the interaction of Syk with its cellular partners while maintaining an active kinase protein. To
achieve this challenging task, we used the powerful potential of intracellular antibodies for the modulation of cellular
functions in vivo, combined to structure-based in silico screening. In our previous studies, we reported the anti-allergic
properties of the intracellular antibody G4G11. With the aim of finding functional mimics of G4G11, we developed an
Antibody Displacement Assay and we isolated the drug-like compound C-13, with promising in vivo anti-allergic activity.
The likely binding cavity of this compound is located at the close vicinity of G4G11 epitope, far away from the catalytic site
of Syk. Here we report the virtual screen of a collection of 500,000 molecules against this new cavity, which led to the
isolation of 1000 compounds subsequently evaluated for their in vitro inhibitory effects using the Antibody Displacement
Assay. Eighty five compounds were selected and evaluated for their ability to inhibit the liberation of allergic mediators from
mast cells. Among them, 10 compounds inhibited degranulation with IC50 values #10 mM. The most bioactive compounds
combine biological activity, significant inhibition of antibody binding and strong affinity for Syk. Moreover, these molecules
show a good potential for oral bioavailability and are not kinase catalytic site inhibitors. These bioactive compounds could
be used as starting points for the development of new classes of non-enzymatic inhibitors of Syk and for drug discovery
endeavour in the field of inflammation related disorders.
Citation: Villoutreix BO, Laconde G, Lagorce D, Martineau P, Miteva MA, et al. (2011) Tyrosine Kinase Syk Non-Enzymatic Inhibitors and Potential Anti-Allergic
Drug-Like Compounds Discovered by Virtual and In Vitro Screening. PLoS ONE 6(6): e21117. doi:10.1371/journal.pone.0021117
Editor: Christian Scho ¨nbach, Kyushu Institute of Technology, Japan
Received April 22, 2011; Accepted May 19, 2011; Published June 20, 2011
Copyright:  2011 Villoutreix et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: We are grateful to INSERM, University of Paris Diderot and ANR Piribio PPIfocusDB. The funders had no role in study design, data collection, and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: piona.dariavach@inserm.fr
Introduction
Development of novel, safe and effective drugs for the treatment
of allergic and autoimmune disorders has been one of the
important research goals of pharmaceutical companies in the past
decade. Protein therapies such as anti-IgE monoclonal antibody
omalizumab (Xolair) for treating allergic airway constriction [1]
and TNFa inhibitors in the field of rheumatoic arthritis and
chronic inflammatory conditions [2] have shown their high
effectiveness, but they can induce side-effects and are expensive
therapies.
Targeting proteins that play a key role in signaling pathways,
such as adhesion molecules or kinases has been another avenue to
address these complex pathologies. Among these targets, the
tyrosine kinase Syk has shown a high potential for the discovery of
new treatments for inflammatory and autoimmune disorders [3].
Syk is a cytoplasmic protein kinase that is a key mediator of
immunoreceptor signaling in B cells, mast cells, macrophages and
neutrophils. Syk is activated at the early stages following the
stimulation of antigen or Fc receptors at the surface of immune
cells, and interacts, via its SH2 domains with a number of
substrates that form macromolecular signaling complexes at the
plasma membrane, and activates signaling pathways that lead
eventually to the inflammatory process (Fig. 1).
Because immunoreceptors including Fc receptors and B cell
receptors are important for both allergic and antibody mediated
autoimmune diseases, interfering with Syk has been a therapeutic
strategy for many pharmaceutical companies. Pharmacological
inhibitors of Syk kinase activity bearing therapeutic potential have
been developed [3,4]. One of these compounds, referred to as
R112, developed by Rigel, has entered clinical trials and showed
remarkable amelioration of allergic rhinitis acute symptoms [5].
An R112-related inhibitor, R406, as well as its orally bioavailable
prodrug, fostamatinib (R788, Rigel) are developed for the
potential treatment of RA. However, such ATP-competitive
kinase inhibitors have limited specificity towards Syk and R406
was shown to inhibit several other kinase and non-kinase targets at
concentrations comparable to those inhibiting Syk [6]. On the
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inhibiting its catalytic activity bears the risk of unwanted
consequences on various physiological functions such as cell
differentiation, adhesion and proliferation [7]. To address this
topic, we opted for the inhibition of the interactions of Syk with its
cellular partners while maintaining an active kinase protein. For
this purpose, we used the powerful potential of intracellular
antibodies for the modulation of cellular functions in vivo [8].
We have reported in a previous work [9] the characterization of
the anti-Syk intracellular scFv G4G11 that binds to a linear
epitope located in the N-terminal SH2 domain of Syk [10]. Our
studies showed that intracellular expression of G4G11 does not
affect the catalytic activity of the kinase, yet inhibits FceRI-
induced release of allergic mediators in a mast cell line [9] (Fig. 1).
With the aim of finding functional mimics of G4G11 that act as
potential inhibitors of the allergic response, we developed an
approach based on an Antibody Displacement Assay for high-
throughput screening of compound collections. Using this
approach, we originally screened a diverse library containing
3000 molecules from which we isolated the drug-like compound
C-13 (Fig. 2), a small molecule that inhibits FceRI-induced mast
cell degranulation in vitro and anaphylactic shock in vivo when
administered orally to mice [10]. Structural analysis and site
directed mutagenesis allowed us to identify the likely binding
cavity of this compound, located at the close vicinity of the scFv
G4G11 epitope, at the interface between the two SH2 domains
and the interdomain A of Syk (Fig. 1). The screened pocket is
distant from the catalytic site, as seen in the low-resolution 3D
structure of Syk determined by single particle electron microscopy
[11]. Accordingly, our functional studies showed that C-13 has no
effects on the enzymatic activity of Syk, but inhibits the
phosphorylation of Syk substrates that form macromolecular
signaling complexes at the plasma membrane that are important
for the activation of mast cells. We concluded that C-13 impedes
protein-protein interactions of Syk with some of its partners [10].
Although identification of protein-protein interaction inhibitors
is a difficult task [12,13], we believe that it could be a very valuable
strategy in the case of Syk. Indeed, several recent success stories
indicate that it is possible to find small molecular probes
modulating macromolecular complex formation [14,15]. Thus,
in an attempt to identify new non-enzymatic inhibitors of Syk and
enlarge our battery of anti-allergic compounds, we performed
structure-based virtual screening experiments of a compound
collection containing 310,000 molecules after filtering, and
targeted the C-13 cavity in Syk that seems to modulate protein-
protein interactions. The top 1000 compounds were evaluated for
their in vitro inhibitory effects using the Antibody Displacement
Assay, and the selected compounds were further characterized in
vivo in a degranulation assay in mast cells. We identified bioactive
compounds different from C-13 with anti-allergic properties that
could be used as starting points for the development of non-
enzymatic inhibitors of Syk, that will help to understand some of
complex molecular mechanisms involving Syk and for drug
discovery endeavour in the field of inflammation related disorders.
Results and Discussion
Structure-based virtual screening against a newly
identified pocket of Syk
In a previous work, we reported that scFv G4G11 binds to a
region of Syk that is important for the binding of protein partners
essential for the degranulation pathway in mast cells [9]. We
wished to find drug-like compounds that act as functional mimics
of G4G11 and identified, through random experimental screening,
the molecule C-13 (Fig. 2), a small compound able to interfere in
vitro with the interaction of G4G11 with Syk (see below). We found
a binding pocket, with a volume of about 755 A
3 compatible with
the binding of a small drug-like compound [16,17], far away from
the catalytic site and located next to the epitope of G4G11, at the
interface between the two SH2 domains and the interdomain A
[10]. With this data in hand, we conducted a structure-based
virtual screening study to identify new classes of compounds that
could bind to this newly identified pocket. We used a hierarchical
virtual screening approach [18] that combined the rigid-body
docking engine MS-DOCK [19] and Surflex (version 2.514)
(incremental construction) [20] (Fig. 3). The ChemBridge
compound collection was used after soft ADMET (absorption,
distribution, metabolism, excretion and toxicity) filtering and soft
assessment for the presence of assay interference, frequent hitter
and reactive compounds with the new version of our tool FAF-
Drugs [21]. The filtering step removed about 190,000 molecules
and the final collection contained 310,000 compounds. The
molecules were generated in 3D with DG-AMMOS [22] and
Multiconf-DOCK [19]. Rigid body docking was carried out with
MS-DOCK [19] in order to select only molecules that would fit in
Figure 1. Schematic diagram of mast cell activation. The newly
identified cavity of Syk is located at the close vicinity of the binding site
of scFv G4G11. The binding of either G4G11 or drug-like compounds to
this area inhibit FceRI-mediated mast cell degranulation.
doi:10.1371/journal.pone.0021117.g001
Figure 2. Structure of compound C-13.
doi:10.1371/journal.pone.0021117.g002
New Classes of Non-Enzymatic Inhibitors of Syk
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21117the binding pocket (i.e., geometric filtering step with only at this
stage evaluation of shape complementarity). This process was
followed by flexible docking with Surflex of the top 60,000
molecules resulting from rigid-body docking. Several groups have
reported [18,23] that such multi-step protocols can speed-up
computations while generally giving better results than full flexible
docking of the entire collection. This observation applies to several
types of binding pockets but not all as, for example, a flat pocket
would obviously not benefit from geometric filtering. However,
here, in the case of Syk, the pocket was judged appropriate since it
forms a relatively pronounced binding groove. The top 2000
molecules after Surflex docking and scoring were analyzed
interactively and 1000 were purchased and subjected to in vitro
and biological assays (Fig. 3).
Experimental screening of the compound collection
To determine the ability of the compounds to affect the binding
of scFv G4G11 to Syk in vitro, we tested them individually in an
ELISA-based Antibody Displacement Assay (see Materials and
Methods). For this purpose, all 1000 compounds were reconsti-
tuted in DMSO, and they were tested at a final concentration of
10 mM in PBS. Compound C-13 was reconstituted in DMF and
was used in parallel as a control. The capacity of each compound
to inhibit the binding of G4G11 to Syk was evaluated in
comparison to the binding of G4G11 to Syk in PBS (final
concentration of 100 nM) containing the appropriate concentra-
tions of DMSO or DMF.
This first in vitro screen led to the isolation of the 85 most active
compounds selected on the basis of their inhibition efficacies
ranging from 11% to 86.5% (Table S1). Compound C-13 used in
parallel displayed 81% inhibition. Direct binding to Syk of a
selection of these 85 compounds was investigated using fluores-
cence spectroscopy. The affinity constants ranged from 0.8-
21.8 mM and suggested that even compounds with low inhibition
efficacies in the Antibody Displacement Assay exhibit good
affinities for Syk (Table 1 and Table S1).
The 85 compounds were clustered into 5 families and 20
singletons, all different from C-13. The two most populated
clusters are clusters 1 and 2, which represent 63 % of these 85
molecules (Fig. 4A). Investigation of these two clusters shows the
systematic presence in cluster 1 of pyrrol-2-one scaffold while
cluster 2 is more diverse and contains compounds with 1,2,4-
triazole, quinazolinone, 1,2,4-triazine or dihydrophtalazin-1-one
Figure 3. In silico screening protocol. Overview of the different steps and computer packages used for the identification of new Syk inhibitors
(see text for details).
doi:10.1371/journal.pone.0021117.g003
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small molecules were likely to bind in the predicted binding pocket
and were either directly (partially protruding onto the epitope
area) or indirectly (conformational changes in the epitope area)
perturbing the binding of the antibody (see below).
Biological effects on mast cell degranulation
The 85 compounds were then tested in a cellular functional
assay in order to evaluate their ability to inhibit the liberation of
allergic mediators from mast cells. The test is based on the
measure of the liberation by exocytosis of the enzyme b-
hexosaminidase following the stimulation of the FceRI, the high
affinity receptor for IgE at the surface of mast cells. To this aim,
RBL-2H3 mast cells were incubated with each compound for one
hour at a final concentration of 20 mM, and b-hexosaminidase
release following FceRI stimulation was measured. Among the 85
molecules, 10 compounds inhibited degranulation with IC50
values #10 mM and interestingly 5 of them belong to cluster 2
(Table 1) and none to cluster 1.
To address the possible toxic effects of these compounds on
degranulation, we performed a dose-dependent experiment in
which FceRI-dependent degranulation of mast cells was per-
formed in parallel with ionomycin-induced degranulation as a
control of the degranulation machinery. We illustrate the results of
this experiment with two compounds which displayed the best
efficacies with IC50 evaluated at 4 mM for both: molecule
7501888 which belongs to cluster 2 and molecule 7722851
which belongs to cluster 5. As shown in Fig. 5, while a specific
inhibition of the liberation of allergic mediators is observed, the
treatment of the cells with ionomycin showed that concentrations
up to 10 mM of the compounds had no major toxic effect on mast
cells responses. The ADMET profile of our 10 bioactive
compounds was analyzed further. This is for instance exemplified
taking 3 interesting molecules (compounds 6282824 and
7501888 belong to cluster 2 and compound 7722851 to cluster
5) that combine biological activity (IC50=425 mM), significant
inhibition of antibody binding (40–67%) and strong affinity for Syk
(Kd=5221 mM) as examples. These molecules have overall a
good potential for oral bioavailability as seen in Fig. 6. Further,
queries into the PubChem database [24] and MDL Drug Data
Report (MDDR) (MDL Drug Data Report (MDDR), version
2010; http://accelrys.com/) for these 10 active compounds
suggest that these molecules are not toxic while they do not seem
to have direct kinase inhibitory activities. In addition, the solubility
was measured experimentally and the Lipinski ‘‘rule of five’’
descriptors [25] were computed to probe further the molecules
from cluster 2 (Table 1). Taken together, our data suggest that
these molecules possess reasonable structures to probe this
biological system and for future chemical optimization.
Structural analysis of selected compounds
In order to propose a possible mechanism of action for our
molecules, we re-docked our best molecules with Surflex (version
2.514) and Molegro Virtual Docker (version 4.3) [26] into the Syk
binding pocket. We illustrate the results of the docking
experiments with molecule 6282824 but we note that for most
compounds, one part of the molecule always seems to be
protruding next to the epitope of scFv G4G11 suggesting that
they could inhibit the binding of the scFv by steric hindrance (see
for example the results for compound 6282824 in Fig. 7). Our
previous studies suggested that the area of Syk interacting with the
antibody G4G11 is also involved in the interaction of Syk with
several, yet not fully elucidated, of its protein partners implicated
in the degranulation pathway. The present data suggest that the
small molecules fit into the Syk binding pocket, protrude at the
molecular surface and could indeed fully or partially inhibit
protein-protein interactions and could thus reduce downstream
degranulation.
Significance
Identification of protein-protein interaction inhibitors is a new
and very active trend in pharmacology. We here combined in silico
screening with an in vitro screening approach that is based on an
antibody displacement assay, to find novel classes of Syk inhibitors
that do not bind to its catalytic kinase site but most likely to a
cavity located in a region essential for protein-protein interactions.
After a series of bioassays, we could identify several drug-like
compounds that showed non-enzymatic inhibition of Syk and that
could be used as a starting point for medicinal chemistry
optimization experiments. These molecules would have valuable
applications in the field of inflammation related disorders.
Materials and Methods
Virtual screening
We used an efficient multistep virtual screening procedure that
is both time- and cost-effective [18,23]. We selected the 500,000-
molecule ChemBridge Corp. compound collection for our study.
Soft Absorption, distribution, metabolism, and excretion/tox
filtering and assay interference compound analysis was performed
with the new version of FAF-Drugs [21]. The remaining 310,000
molecules were docked into a Syk pocket that we have recently
discovered and characterized [10]. The binding pocket for docking
was defined using several in silico procedures including the Surflex
protomol utility and by the ICM pocket finder utility (Molsoft LLC,
La Jolla, CA, USA) and validated by site directed mutagenesis as
described by Mazuc et al. [10]. The X-ray structure of Syk SH2
domains, PDB code 1A81, was used [27]. The ICM regularization
procedure was applied in order to optimize of hydrogen bond
Table 1. Five most bioactive compounds from cluster 2.
ID ChemBridge IC50 Cell Degranulation (mM) Kd (mM) Solubility (mM) Lipinski Violations
6197026 (C-13) 2 4 ND 1 (log P)
6282824 55 . 6 4 . 5 0
7495334 10 1.6 35.2 0
7501888 4 8.2 6 2 (log P, MW)
7752193 10 8 0.3 0
7783660 10 4.8 12.9 1 (MW)
Compound C-13 is included as a reference.
doi:10.1371/journal.pone.0021117.t001
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clustering. (B) Structures of the most bioactive molecules from cluster 2.
doi:10.1371/journal.pone.0021117.g004
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resulted in two important changes in the structure: reorientation of
the side chain of N11, and rebuilding of the K124 side chain, both
residues being located in the predicted binding zone. Numerous
other small adjustments were also noticed in the structure as
expected from the regularization procedure. The protonation state
of the histine residues during docking was kept as defined by ICM
(nonionized). Additional investigations of the protonation state of
titratable groups were performed through electrostatic computa-
tions with our PCE server [18,24] and charges assigned
accordingly within Chimera [28]. The electrostatic computations
were carried out with two dielectric constants: 4 and 11 for the
solute, and 80 for the solvent. Both runs showed normal titration
behavior for all titratable groups of the binding zone.
The 3D structures of the small compounds were generated with
DG-AMMOS [22] employing a distance geometry method and up
to 50 conformers were generated for each ligand with Multiconf-
DOCK [19] applying an energy window of 25 kcal.mol
21 and a
diversity threshold of 0.8 A ˚ RMSD. These values represent an
appropriate balance between speed for the subsequent rigid-body
docking, and the accuracy in terms of finding bioactive conforma-
tions among a conformational ensemble [19,29,30]. MS-DOCK is
a protocol for multiple conformation rigid body docking that uses
the docking engine DOCK [31] in which the score evaluates only
the stericcomplementarity between the ligand and the protein using
a contactscoringfunctionthatcountsthenumberofreceptor-ligand
contacts within a 4.5 A ˚ distance from any ligand atom. The allowed
bump overlap waschosen to be 0.50(by default 60) permitting some
minor clashes between the atoms of the protein binding pocket and
the ligands. It was previously shown that 0.5 is the best bump
overlap value in case of a closed and well-formed pocket (see for
details [19]), as it is the case here as the targeted zone forms a
relatively narrow groove. MS-DOCK is able to successfully reduce
the initial chemical library by 2- or 3-fold depending on the binding
site shape and volume [19]. Here, because the binding site is a well
formed, we suggest that our shape complementarity filter can be
used efficiently. After analysis of the pocket and from our previous
benchmarking of our MS-DOCK tool, we decided to keep only the
top 60,000 compounds scored by MS-DOCK among our
compound collection of 310,000 molecules [31].
The flexible docking was then performed on the 60,000
molecules using Surflex v.2.514 with the multistart parameter on
(5 starting positions). The docking step was performed using the
protomol based on the residue list validated by mutagenesis [10]
with an extension of 2 A ˚ (the parameter proto_bloat was set to 2,
the default value is 0). For the postprocessing, the following
parameters were used: the ‘‘polar’’ term was set to 2 because
several charged/polar residues are present in the binding pocket
Figure 5. Compounds 7501888 and 7722851 impair FceRI-induced mast cell degranulation. b-hexosaminidase release from mast cells
was evaluated in comparison to ionomycin-induced degranulation as a control of the machinery.
doi:10.1371/journal.pone.0021117.g005
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violations because the pocket is relatively closed, thus the ‘‘crash’’
value was set to 23.0 (the default value is 21). The top 2,144
docked ligands with a Surflex score superior to 7.0 (i.e., a very
good score in Surflex) were analyzed using PyMOL (DeLano, San
Carlos, CA) and 1000 molecules were selected after visual
inspection and purchased. Keeping in mind that the most active
compounds found experimentally have a Surflex score between
9.5 and 7.9, we believe that the applied threshold of 7.0 used in the
present study was appropriate for this cavity.
Some selected compounds were re-docked with Surflex v.2.514
turning on several optimization parameters to enhance the search
and refine poses [20] and with Molegro Virtual Docker [26]. To
re-dock the best active compounds, the following changes were
applied to Surflex: the ‘‘pgeom’’ option was used with the
clustering RMSD between the poses set to 0.9 A ˚ instead of the
default value of 0.5 A ˚, and 30 poses saved for the structural
analysis. Regarding re-dock with Molegro, ligand and protein
atoms were prepared within the Molegro package. The detect
cavity procedure was applied employing a grid method searching
for accessible volumes defined as zones where a sphere probe does
not clash with the protein atoms. The cavities found are then
ranked according to their volume. The top cavity ranked by
Molegro matches with the region probed by site directed
mutagenesis. We constrained the search to this cavity by adding
a penalty to poses that were found well outside the binding regions.
The grid-based scoring function used in this re-docking involves:
interaction energy terms between the protein and the ligand
(hydrogen bonds, van der Waals interactions, and electrostatic
interactions modeled as a Coulomb potential with a distance-
dependent dielectric constant), ligand internal energy and, as
mentioned above, a penalty if the ligand pose was found to be too
far away from the binding cavity (in our case a sphere with a
radius of 15 A ˚ around the center of the detected cavity). Ten poses
were generated with the RMSD between the poses .1A ˚. In order
to optimize the ligand poses for a more precise structural analysis,
we employed several options not activated by default, namely the
ligand internal energy and the penalty if the ligand is placed
outside of the required zone, and energy minimization of the
ligand poses.
The Ligand-info package [32] was used for clustering the 85
compounds that were found to be interesting experimentally. The
clusteringapproachuses two-dimensionalstructure similaritysearch.
The compounds are represented by modified hashed-fingerprints
and the algorithm computes for each molecule a vector of two-
dimensional indices as well as their occurrence counts. A Tanimoto
similarityindexisthenusedtoassessthe similaritybetween allpairof
compounds and takes values between 0 and 1, where 0 means that
Figure 6. Physico-chemical profile of compounds 6282824, 7501888, 7722851. A radar plot representing the computed oral bioavailability
profile (compound blue line should fall within the optimal green area, white and red ones being extreme zones generally indicating low oral
bioavailability). This analysis was carried out on all molecules but we present the data only for three compounds. The computations involved: logP,
molecular weight (MW), topological polar surface area (tPSA), rotatable bond (RotB), H-bonds acceptors and donors (HBA, HBD).
doi:10.1371/journal.pone.0021117.g006
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both molecules are composed of identical sets of indices.
Selection of Drug-Like Compounds (ADMET with FAF-
Drugs2)
We decided to use our ADMET filtering package that combines
physicochemical filtering and removal of some reactive groups and
some compounds that could interfere with assays. Property cutoff
values used to select drug-like species follow the ones reported by
Irwin and Shoichet [33]: 60, MW ,600, 0, HBDonnors ,6, 0,
HBAcceptors ,11, 0, Rotatable Bonds ,12, 0 , Rigids Bonds
,50, 0, Number of Rings ,7, Size of Biggest Ring ,12, 0,tPSA
,150, 24,logP ,6.0. Finally, undesirable moieties and chemical
substructures known to interfere during in vitro bioassays were
removes such as, quinone, epoxide, michael acceptors and nitroso.
Figure 7. Predicted structure of the complex between compound 6282824 and Syk. (A) The small molecule was docked into a binding
pocket previously identified by our groups and located far away from the catalytic site. We suggest that the mechanism of action for the small
molecule involves either or both, small local structural changes in nearby loops thereby impeding appropriate contacts between Syk and some
protein partners or that the small molecule directly clashes into upcoming proteins that interact with Syk. (B) Structural analysis of a possible binding
pose. A zoom in the binding pocket and rotations were carried out as compared to panel A in order to facilitate the reading of the figure. Side chains
mutated in our previous study are shown in dark blue and additional amino acids expected to be important for binding are shown in yellow. The
residues found important in our previous mutagenesis study [10] involves Glu 121, Glu 155, and Arg 68. Two hydrogen bonds between the
compound and Lys 156 and Ala 10 (backbone N atom) are predicted with a likely electrostatic interaction between Glu 121 and the triazole ring.
Hydrophobic, aromatic and pi stacking interactions are also predicted, the main side chains involved are Phe 16, Leu 48, and the hydrophic moiety of
the Arg 68 and Glu 155 side chains.
doi:10.1371/journal.pone.0021117.g007
New Classes of Non-Enzymatic Inhibitors of Syk
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21117Chemicals and antibodies
Small molecules were purchased from ChemBridge Corp. San
Diego, USA, and stock solutions were prepared at 10 mM in
DMSO, except for compound referred to as C-13 (methyl 2-{5-
[(3-benzyl-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene) methyl]-2-fur-
yl}benzoate, ChemBridge ID number 6197026) which was
prepared at 10 mM stock solution in DMF. All reagents unless
otherwise mentioned were from Sigma. The hapten dinitrophenyl
(DNP) was purchased from Calbiochem. HRP-conjugated mAb
9E10 was from Santa Cruz Biotechnology. The anti-Syk scFv
G4G11 was produced as previously described [34].
Solubility measurements
4 ml of a 10 mM DMSO stock solution from of each sample
were dissolved in 400 ml of PBS and sonicated for 5 minutes. The
samples were centrifuged for 15 minutes at 4000 rpm at 25uC,
then 250 ml of each sample were transferred to a 96 well plate.
10 ml of each sample were analyzed by HPLC and the sample
concentrations were calculated against a series of caffeine
standards ranging from 1 to 100 mM.
Antibody Displacement Assay
Recombinant GST:Syk 6-242 fusion protein [34] was immo-
bilized on an ELISA plate at final concentration of 10 mgm l
21.
For the screening assay, small molecules diluted in PBS at final
concentration of 10 mM were added to the wells for one hour at
RT, before adding myc-tagged scFv G4G11 at final concentration
of 100 nM for one additional hour. The binding of G4G11 to Syk
was evaluated by adding HRP-conjugated mAb 9E10 which
detects the amino acid sequence EQKLISEEDLN of human c-
myc protein located at the C-terminal end of the scFv.
Cells, culture conditions and functional assays
The mouse IgE anti-DNP monoclonal antibody 2682-I was
used as hybridoma culture supernatants which contained 1 mg
ml
21 IgE. RBL-2H3 rat basophilic leukaemia cells (ATCC) were
maintained as monolayer cultures in RPMI 1640 medium
supplemented with 10% fetal bovine serum (Gibco). Measure-
ments of b-hexosaminidase release in RBL-2H3 cells were
performed as described [9], except that after 12–16 h incubation
with anti-DNP IgE (0.5 mgm l
21), cells were incubated for 90 min
at 37uC in RPMI medium supplemented with the indicated
concentrations of small molecules or DMSO (0.25%). Cells were
challenged for 45 min with DNP-BSA (50 ng ml
21).
Supporting Information
Table S1 The 85 most active compounds selected after
in silico and in vitro screen. For each compound, the
ChemBridge ID and the cluster to which it belongs are reported.
Direct binding to Syk of some compounds was measured using
fluorescence spectroscopy (Kd: dissociation constant). Antibody
inhibition percentage reflects the capacity of each compound to
inhibit the binding of scFv G4G11 to Syk (final concentrations of
10 mM for small molecules and 100 nM for G4G11). The ability
of each compound to inhibit the liberation of allergic mediators
from mast cells is measured (**:I C 50 values of cell degranulation
$20 mM). Some physicochemical properties computed with
FAFDrugs2, as well as the possible ADMET problems detected
by our tool are reported. The computations involved: molecular
weight (MW), logP, topological polar surface area (tPSA), H-bond
acceptors and donors (HBA, HBD).
(PDF)
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